Teriparatide news

All news on Teriparatide (also known as Teribone™ Injection): plants, production capacities, investments and involved companies.

19 February 2026

Asahi Kasei Pharma Partners with MAIA for U.S. Teribone™ Development

MAIA will develop and commercialize Teribone™ in the U.S. to address the growing osteoporosis patient population, expanding access to proven bone-forming therapy.
30 October 2025

Aptar Q3 2025 Financial Results

Sales up 6%, net income up 28%, EPS up 30%. Strong growth in Pharma and Closures. $70M returned to shareholders.

Who will be producing Teriparatide in the future?

Find out with chemXplore Analytics